Tang Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Tang Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,070,209	Closed	-$7.85M	–	91
2025 Q3	$7.85M	Hold	2,070,209	–	–	0.3%	75
2025 Q2	$5.13M	Hold	2,070,209	–	–	0.26%	81
2025 Q1	$3.21M	Hold	2,070,209	–	–	0.18%	100
2024 Q4	$4.43M	Buy	2,070,209 +700,000	+51%	+$2.01M	0.29%	78
2024 Q3	$5.96M	Sell	1,370,209 -232,991	-15%	-$1.27M	0.43%	67
2024 Q2	$7.47M	Hold	1,603,200	–	–	0.76%	41
2024 Q1	$8.13M	Sell	1,603,200 -200,000	-11%	-$806K	0.85%	40
2023 Q4	$5.07M	Buy	1,803,200 +1,403,200	+351%	+$3.29M	0.47%	55
2023 Q3	$1.15M	Buy	+400,000	New	+$1.47M	0.16%	86

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tang Capital Management's BDTX Position: Q4 2025 in Review

Tang Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q4 2025, closing a stake of 2,070,209 shares — an estimated $7.85M sold.

Tang Capital Management first reported a position in BDTX in Q3 2023 and held it in 9 quarters. The position peaked at $8.13M in Q1 2024. 104 funds tracked by Wall St. Rank hold BDTX as of Q4 2025.

Tang Capital Management reported no remaining Black Diamond Therapeutics position as of Q4 2025 after selling out during the quarter.
Tang Capital Management sold 2,070,209 Black Diamond Therapeutics shares in Q4 2025, an estimated $7.85M.
Tang Capital Management first reported a position in Black Diamond Therapeutics in Q3 2023 and held it in 9 quarters.
Tang Capital Management's Black Diamond Therapeutics position peaked at $8.13M in Q1 2024.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.